TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25213640
Drug: Pain induced
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain induced by injection of hypertonic saline into vastus medialis (VM)
Study: 25213640
Drug: Pain induced
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain induced by injection of hypertonic saline into rectus femoris (RF)
Study: 12169127
Drug: Aminoglycoside and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoglycoside and steroid preparation
Study: 12169127
Drug: Steroid preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid preparation without aminoglycoside
Study: 10451909
Drug: Intranasal GHRH
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal GHRH (300 micrograms)
Study: 8963361
Drug: Low fat/high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fat/high fiber diet (25.5 energy‐% fat, 58.5 energy‐% carbohydrate, 3.9 g dietary fiber/MJ)
Study: 1978471
Drug: Remoxipride twice
Normalized name: remoxipride
DrugBank: Remoxipride (DB00409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxipride twice daily
Study: 1978471
Drug: Remoxipride three
Normalized name: remoxipride
DrugBank: Remoxipride (DB00409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxipride three times daily
Study: 1978471
Drug: Haloperidol three
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol three times daily
Study: 111119
Drug: Cefoxitin, 2
Normalized name: CefOXitin, 2 g injectable powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin, 2 g, intramuscularly
Study: 111119
Drug: Procaine penicillin
Normalized name: procaine penicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaine penicillin G, 4.8 million U, intramuscularly
Study: 31338640
Drug: Topical lotion
Normalized name: Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lotion CG428, applied twice per day for 6 months
Study: 31338640
Drug: Placebo, applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, applied twice per day for 6 months
Study: 15232329
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 to 40 mg/d)
Study: 15232329
Drug: Imipramine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (75 to 200 mg/d)
Study: 9241284
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g of elemental calcium for 6 weeks
Study: 8231904
Drug: 17 beta‐oestradiol-releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 beta‐oestradiol-releasing vaginal ring (53 mg)
Study: 3619421
Drug: 50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/kg mezlocillin
Study: 3619421
Drug: 80 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/kg mezlocillin
Study: 22095545
Drug: Fosfomycin/tobramycin for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfomycin/tobramycin for inhalation (FTI) 160/40 mg
Study: 22095545
Drug: Fosfomycin/tobramycin for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfomycin/tobramycin for inhalation (FTI) 80/20 mg
Study: 1554660
Drug: PGE2 gel
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2 gel (2 mg) instilled into the posterior fornix, with a further dose of 1 mg if contractions did not commence after 6 hours
Study: 27136412
Drug: High-dose aerobic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose aerobic exercise
Study: 23945965
Drug: Nifedipine controlled-release
Normalized name: nifedipine Extended Release Oral Tablet [Afeditab CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine controlled-release 40 mg b.i.d.
Study: 23945965
Drug: Nifedipine controlled-release
Normalized name: nifedipine Extended Release Oral Tablet [Afeditab CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine controlled-release 40 mg q.d.
Study: 19250152
Drug: Online cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online cognitive behavioural therapy (CBT)
Study: 20487589
Drug: 48 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48 g/d WG cereal (WGM)
Study: 20487589
Drug: 48 g
Normalized name: GLYCERIN 3 g in 48 g CUTANEOUS OINTMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48 g placebo cereal (non‐whole grain (NWG))
Study: 15692967
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide for treatment of SSc-associated interstitial lung disease
Study: 11965271
Drug: Nicorandil 20
Normalized name: nicorandil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil 20 mg twice daily
Study: 7734095
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg twice daily for 1 week)
Study: 7009264
Drug: Mixed meals
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed meals (20, 40, and 60 g of complex carbohydrate)
Study: 7009264
Drug: Dextrose (20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose (20, 40, and 60 g)
Study: 28955715
Drug: siponimod 2
Normalized name: siponimod 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: siponimod 2 mg once daily (preceding treatment)
Study: 28955715
Drug: siponimod 2
Normalized name: siponimod 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: siponimod 2 mg once daily (interrupted treatment)
Study: 28955715
Drug: siponimod 2
Normalized name: siponimod 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: siponimod 2 mg once daily (concomitant treatment)
Study: 28955715
Drug: siponimod 2
Normalized name: siponimod 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: siponimod 2 mg once daily (all groups)
Study: 21069381
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBOT) at 2.0 atm with inhalation of 100% oxygen for 60 min at 3, 24, and/or 48 hours after hepatectomy.
Study: 16897112
Drug: Stanger bath
Normalized name: Stangard
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stanger bath therapy combined with amitriptyline (10 mg/day for 8 weeks)
Study: 16897112
Drug: Amitriptyline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (10 mg/day for 8 weeks) alone
Study: 14962012
Drug: Theophylline 7
Normalized name: theophylline 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline 7 mg kg‐1
Study: 11274240
Drug: High-dose omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose omega-3 fatty acids (EPA 3.76 g and DHA 2.94 g daily)
Study: 11274240
Drug: Low-dose omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose omega-3 fatty acids (EPA 1.88 g and DHA 1.47 g daily)
Study: 9674329
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil suspension, 15 mg/kg, single oral dose
Study: 5171687
Drug: Expressed human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Expressed human milk and proprietary breast-milk substitute (S26) with protein intake of not more than 4.5 g/kg/day
Study: 5171687
Drug: Evaporated milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaporated milk formula with protein intake ranging from 6.15 to 12.3 g/kg/day
Study: 31672458
Drug: Sevelamer (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevelamer (1600 mg three times daily)
Study: 28768531
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Glycopyrronium + Indacaterol)
Study: 25511789
Drug: Levetiracetam (LEV),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (LEV), 500 mg/body every 12 hours until postoperative day 7
Study: 25511789
Drug: Phenytoin (PHT),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin (PHT), 15-18 mg/kg fosphenytoin followed by 125 mg PHT every 12 hours until postoperative day 7
Study: 23332040
Drug: Biofortified cassava
Normalized name: cassava
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofortified cassava porridge with added oil (2 mg β-carotene, 15 ml peanut or rapeseed oil, 20 g total fat)
Study: 23332040
Drug: Biofortified cassava
Normalized name: cassava
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofortified cassava porridge without added oil (2 mg β-carotene, 6 g total fat)
Study: 23332040
Drug: Unfortified white
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfortified white cassava porridge with added oil (0.3 mg retinyl palmitate, 20 g total fat)
Study: 8849179
Drug: Pefloxacin 400
Normalized name: pefloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin 400 mg
Study: 30341109
Drug: Arrabidaea chica
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arrabidaea chica herbal gel (2.5% standardised extract)
Study: 28934783
Drug: Vertebral augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vertebral augmentation using a polyetheretherketone implant
Study: 26312480
Drug: DPP treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPP treatments (specific treatments not detailed)
Study: 20828943
Drug: Disulfiram 62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram 62.5 mg/day
Study: 20828943
Drug: Disulfiram 125
Normalized name: disulfiram 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram 125 mg/day
Study: 10467834
Drug: C-reactive protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-reactive protein (CRP) estimation during treatment
Study: 7883114
Drug: T-cell reactivity
Normalized name: Virus Specific T-Cell
DrugBank: Virus Specific T-Cell (DB15735)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-cell reactivity to beta-cell membrane preparation enriched for insulin-secretory granule antigen in newly diagnosed IDDM patients
Study: 7883114
Drug: T-cell reactivity
Normalized name: Virus Specific T-Cell
DrugBank: Virus Specific T-Cell (DB15735)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-cell reactivity in children in remission for insulin dependency (honeymoon period)
Study: 385093
Drug: Progesterone 200
Normalized name: progesterone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone 200 mg b.d.
Study: 385093
Drug: Progesterone 400
Normalized name: progesterone 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone 400 mg b.d.
Study: 23967738
Drug: ADV (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADV (10 mg/day, orally) plus peg‐IFN (180 microg/week, subcutaneous injection) for 48 weeks
Study: 23967738
Drug: ADV plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADV plus LAM (100 mg/day, orally) for 48 weeks followed by continued LAM treatment for an additional 24 weeks
Study: 22086229
Drug: Intravesical gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical gemcitabine 2,000 mg once per week for 6 weeks
Study: 11575342
Drug: Amrinone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amrinone (5 microg kg(‐1) min(‐1) after a loading dose of 1.0 mg kg(‐1))
Study: 7889898
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (2.4 g n‐3 fatty acids)
Study: 29752345
Drug: Dual-hormone closed-loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-hormone closed-loop system
Study: 29752345
Drug: Single-hormone closed-loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-hormone closed-loop system
Study: 22910287
Drug: ID3 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ID3 (3 μg HA per strain)
Study: 22910287
Drug: ID9 (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: ID9 (9 μg HA per strain)
Study: 22910287
Drug: INT9 (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: INT9 (9 μg HA per strain)
Study: 22910287
Drug: IM15 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM15 (15 μg HA per strain)
Study: 10640975
Drug: Neoadjuvant androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant androgen deprivation therapy (ADT) for 3 months followed by radical prostatectomy (RP)
Study: 3330031
Drug: Nitrendipine (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (5-20 mg b.d.)
Study: 3330031
Drug: Propranolol (40-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40-120 mg b.d.)
Study: 29705484
Drug: Cold therapy
Normalized name: Deep Cold Therapy
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold therapy (ice packs for 20 minutes prior to chest tube removal)
Study: 29705484
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (listening to music for 30 minutes starting 15 minutes prior to chest tube removal)
Study: 29705484
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cold and music therapy
Study: 11195032
Drug: Isotonic sodium
Normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic sodium chloride solution
Study: 21189767
Drug: Gantrez‐NNP combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gantrez‐NNP combination
Study: 18729245
Drug: 500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/day EFLA943 for 8 weeks
Study: 18729245
Drug: 1000 mg/day
Normalized name: RibaTab 1000 MG/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/day EFLA943 for 8 weeks
Study: 18729245
Drug: Low-dose group
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose group (500 mg/day EFLA943)
Study: 18729245
Drug: High-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose group (1000 mg/day EFLA943)
Study: 10340912
Drug: SB 209670
Normalized name: SB 224289
DrugBank: SB 224289 (DB17052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB 209670 infusion at doses ranging from 0.2 to 1.5 microg kg(‐1) min(‐1) for approximately 8 hours
Study: 7582196
Drug: Cilazapril 2
Normalized name: cilazapril 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 2 mg daily, starting 7 days before PTCA and continuing for 6 months
Study: 28523795
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health literacy intervention (5 sessions, 1.5 hours each over 1 year)
Study: 28523795
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health literacy intervention
Study: 9241623
Drug: Enalapril (2.5‐5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (2.5‐5 mg daily)
Study: 3430295
Drug: Griseofulvin 1
Normalized name: griseofulvin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Griseofulvin 1 g daily
Study: 31665912
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intrapancreatic autologous stem cell (ASC) infusion and hyperbaric oxygen treatment (HBOT)
Study: 20717048
Drug: Anterior lens
Normalized name: lens scale pollen extract
DrugBank: Atriplex lentiformis pollen (DB10760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior lens capsule
Study: 19615288
Drug: Thalidomide 200
Normalized name: thalidomide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide 200 mg orally daily + vinorelbine 25-30 mg/m² i.v. on D1 and D8 + cisplatin 70-80 mg/m² i.v. on D1
Study: 19615288
Drug: Vinorelbine 25-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 25-30 mg/m² i.v. on D1 and D8 + cisplatin 70-80 mg/m² i.v. on D1
Study: 17414229
Drug: Prasugrel (LD/MD:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (LD/MD: 20/5 mg, 30/7.5 mg, 40/10 mg, 60/15 mg)
Study: 17414229
Drug: Prasugrel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel plus ASA (325 mg)
Study: 11853116
Drug: Drug-free and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-free and drug-naive patients
Study: 2804589
Drug: Adjusted low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted low dose heparin prophylaxis
Study: 2804589
Drug: Fixed low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed low dose heparin prophylaxis (calcium heparin 5000 units, 8‐hourly)
Study: 5328359
Drug: Protryptiline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protryptiline (10 mg three times daily, max 60 mg daily)
Study: 29354915
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acupoint catgut-embedding therapy and auricular point pressure
Study: 23322522
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of epirubicin and paclitaxel alone or with capecitabine (TEX)
Study: 17185877
Drug: Mitiglinide regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitiglinide regimen (mitiglinide combined with once daily insulin glargine)
Study: 17185877
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin regimen (multiple daily insulin regimen of aspart insulin and glargine)
Study: 14678008
Drug: 4.5% human
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5% human albumin solution (HAS)
Study: 2519937
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg of 0.5% bupivacaine IP
Study: 1101457
Drug: Cyclandelate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclandelate (200 mg four times daily for six weeks)
Study: 30987704
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (oral) for 2 months
Study: 16817274
Drug: Point application
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Point application at Yishu, Pishu, Sanyinjiao, Zusanli, and interference therapy of controlling diet
Study: 16817274
Drug: Interference therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interference therapy of controlling diet
Study: 10360858
Drug: Ropivacaine 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 1.2 mg/kg
Study: 10360858
Drug: Ropivacaine 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 1.8 mg/kg
Study: 23338109
Drug: Lidocaine 3
Normalized name: Lidocaine 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 3 mg/kg
Study: 7075649
Drug: Pindolol 15
Normalized name: pindolol 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol 15 mg twice daily
Study: 7075649
Drug: Pindolol 30
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pindolol 30 mg retard once daily
Study: 7075649
Drug: Pindolol 30
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pindolol 30 mg retard
Study: 28427403
Drug: 12.5% maltodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5% maltodextrin (200 ml, 2 h before anesthesia) without ω-3 PUFA (CHO, n=14)
Study: 28427403
Drug: 12.5% maltodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5% maltodextrin (200 ml, 2 h before anesthesia) plus intraoperative ω-3 PUFA (0.2 mcg/kg) (CHO + W3, n=15)
Study: 28427403
Drug: Water (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (200 ml, 2 h before anesthesia) plus intraoperative ω-3 PUFA (0.2 mcg/kg) (W3, n=14)
Study: 28427403
Drug: Water (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (200 ml, 2 h before anesthesia) without ω-3 PUFA (controls, n=14)
Study: 18063411
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BTX‐A) treatment
Study: 25773465
Drug: 0.5% menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% menthol gel
Study: 30861160
Drug: 4-mg FDA-approved
Normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-mg FDA-approved nasal spray
Study: 30861160
Drug: 2-mg FDA-approved
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-mg FDA-approved autoinjector
Study: 30861160
Drug: Improvised nasal
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Improvised nasal naloxone device (INND) administered twice (2 mg each, separated by 2 minutes)
Study: 29928996
Drug: ACT+CEE (Combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT+CEE (Combination of ACT and CEE)
Study: 18722112
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NACT) followed by breast conservation surgery with axillary dissection and radiation
Study: 17204566
Drug: Chondroitin sulphate
Normalized name: Chondroitin sulphate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin sulphate (1 g/day)
Study: 9474617
Drug: Winstrol (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Winstrol (6 mg per day) for 16 ± 9 weeks
Study: 2191444
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with antibiotic therapy
Study: 2191444
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with adrenal corticosteroid therapy
Study: 205020
Drug: Prophylactic adenine
Normalized name: Adenine
DrugBank: Adenine (DB00173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic adenine arabinoside (Ara-A) at a dose of 5 mg/kg/day administered intravenously on an intermittent schedule
Study: 30634878
Drug: Conventional mirror
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional mirror book (MB) therapy
Study: 19785937
Drug: BMMC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMMC therapy
Study: 8147083
Drug: Re-activating occupational
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-activating occupational therapy (study group)
Study: 29206647
Drug: Acute intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute intravenous sodium loading (hypertonic saline 5 mmol sodium/liter body water for 30 minutes)
Study: 29206647
Drug: Acute intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute intravenous sodium loading
Study: 20480060
Drug: Brushing with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brushing with 1 g of F-containing dentifrice (0.32% NaF)
Study: 2246313
Drug: Standard antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antibiotic bowel preparation